HC Wainwright Forecasts Journey Medical Q1 Earnings

Journey Medical Corporation (NASDAQ:DERM) – Stock analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Journey Medical in a research report issued to clients and investors on Wednesday, March 25th. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of ($0.05) per share for the quarter. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for Journey Medical’s Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.17 EPS, FY2026 earnings at $0.16 EPS, FY2027 earnings at $1.16 EPS, FY2028 earnings at $1.76 EPS, FY2029 earnings at $1.90 EPS and FY2030 earnings at $2.01 EPS.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Journey Medical in a research report on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $13.00.

Journey Medical Stock Down 30.0%

Journey Medical stock opened at $4.78 on Friday. The stock has a market cap of $158.97 million, a PE ratio of -10.17 and a beta of 0.81. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.12 and a current ratio of 1.42. Journey Medical has a one year low of $4.76 and a one year high of $9.56. The stock has a fifty day moving average of $8.00 and a 200 day moving average of $7.80.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02. The firm had revenue of $16.08 million for the quarter, compared to analysts’ expectations of $18.86 million. Journey Medical had a negative return on equity of 51.42% and a negative net margin of 18.48%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Journey Medical in the 2nd quarter worth $29,000. Bank of America Corp DE lifted its position in Journey Medical by 4,707.0% during the second quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock valued at $30,000 after purchasing an additional 4,048 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Journey Medical during the second quarter valued at about $36,000. JPMorgan Chase & Co. bought a new stake in Journey Medical during the second quarter valued at about $41,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Journey Medical in the second quarter worth about $48,000. Hedge funds and other institutional investors own 7.25% of the company’s stock.

Journey Medical News Summary

Here are the key news stories impacting Journey Medical this week:

• Positive Sentiment: Strong Emrosi uptake and FY‑2025 results: Management reported FY2025 revenue of $61.9M, Emrosi generated $14.7M in net revenues with ~53,000 prescriptions filled since its April 2025 launch, and payer access now covers >100M U.S. commercial lives — data that support faster revenue scaling and path to profitability. GlobeNewswire: Full‑Year 2025 Results
• Positive Sentiment: HC Wainwright reiterates Buy and $13 price target with bullish long‑term EPS trajectory: The firm keeps a Buy rating and projects multi‑year EPS growth (FY2027–FY2030 forecasts rising to $1.16 → $2.01), which supports investor optimism about valuation upside versus current levels. MarketBeat: Analyst Note (HC Wainwright)
• Neutral Sentiment: Q4 2025 EPS beat but revenue missed: Journey reported Q4 EPS of ($0.04), beating consensus (‑$0.06) by $0.02, yet revenue of $16.08M missed estimates (~$18.86M). The EPS beat eases near-term concerns, but the top‑line shortfall highlights execution and adoption timing risks. MarketBeat: Q4 Earnings & Call
• Negative Sentiment: HC Wainwright trims some medium‑term estimates: Although still constructive, the firm lowered FY2026–FY2030 estimates slightly (e.g., FY2026 to $0.16 from $0.18; small downticks to FY2027–FY2029 forecasts), indicating tempered near‑term margin/volume assumptions that could limit immediate upside. MarketBeat: Analyst Revisions

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.